Becher, Peter Moritz http://orcid.org/0000-0003-1221-7015
Goßling, Alina
Fluschnik, Nina
Schrage, Benedikt
Seiffert, Moritz
Schofer, Niklas
Blankenberg, Stefan
Kirchhof, Paulus
Westermann, Dirk
Kalbacher, Daniel
Funding for this research was provided by:
Universitätsklinikum Hamburg-Eppendorf (UKE)
Article History
Received: 30 June 2022
Accepted: 2 September 2022
First Online: 12 September 2022
Declarations
:
: Dr. Becher was partially supported by the German Research Foundation (Grant number BE 7424/2–1). Dr. Schrage received funding from the German Research Foundation and the Else Kröner-Fresenius-Stiftung, and speakers fees from Astra Zeneca as well as Abiomed, outside from the submitted work. Dr. Seiffert reports non-financial support from Abbott Vascular, personal fees from Abiomed, personal fees from AstraZeneca, personal fees from Bayer Healthcare, non-financial support from Biotronik, personal fees from Boehringer Ingelheim, grants, personal fees and non-financial support from Boston Scientific, personal fees from Bristol-Myers Squibb, non-financial support from Edwards Lifesciences, non-financial support from Nicolai Medizintechnik, non-financial support from OrbusNeich Medical, grants and personal fees from Philips, personal fees from Medtronic, personal fees from Amgen, personal fees from Shockwave Medical, personal fees from Daichii Sankyo, personal fees from Pfizer, personal fees from Siemens Healthineers, outside the submitted work. Dr. Schofer received lecture fees from Edwards Lifesciences, all outside the submitted work. Dr. Kirchhof was partially supported by European Union BigData@Heart (grant agreement EU IMI 116074), AFFECT-AF (grant agreement 847770), and MAESTRIA (grant agreement 965286), British Heart Foundation (AA/18/2/34218), German Center for Cardiovascular Research supported by the German Ministry of Education and Research (DZHK), and Leducq Foundation. PK receives research support for basic, translational, and clinical research projects from European Union, British Heart Foundation, Leducq Foundation, Medical Research Council (UK), and German Centre for Cardiovascular Research, from several drug and device companies active in atrial fibrillation and has received honoraria from several such companies in the past, but not in the last three years. PK is listed as inventor on two patents held by University of Birmingham (Atrial Fibrillation Therapy WO 2015140571, Markers for Atrial Fibrillation WO 2016012783). Dr. Blankenberg reports grants from Abbott Diagnostics, Siemens, Singulex, grants and personal fees from Bayer, Thermofisher, personal fees from Novartis, outside the submitted work; and payments or honoraria for lectures, presentations, speaker bureaus, manuscript writing or educational events, support for attending meetings and travel from Abbott, AstraZeneca, Bayer, Amgen, Medtronic, Pfizer, Siemens and Thermofisher, all outside the submitted work. Dr. Westermann reports personal fees from Abiomed, AstraZeneca, Bayer, Berlin-Chemie, Boehringer Ingelheim, Novartis, all outside the submitted work. Dr. Kalbacher received proctor and lecture fees from Edwards Lifesciences and lecture fees from Abbott Medical, all outside the submitted work. Dr. Fluschnik and Mrs. Goßling have no COI to declare.